Methotrexate and Misoprostol to Terminate Early Pregnancy

Hausknecht, Richard

doi:10.1056/nejm199508313330901

Cited by 155 publications

(39 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Once Hausknecht [2] demonstrated that women could leave the office as soon as misoprostol was administered and handle the expulsion on their own, subsequent studies explored dispensing misoprostol to women for home use. These studies demonstrated that women were able to follow instructions and take the misoprostol as directed and led to the elimination of a clinic visit.…”

mentioning

confidence: 99%

If we can do it for misoprostol, why not for mifepristone? The case for taking mifepristone out of the office in medical abortion

Gold

Chong

2015

Contraception

View full text Add to dashboard Cite

mentioning

confidence: 99%

If we can do it for misoprostol, why not for mifepristone? The case for taking mifepristone out of the office in medical abortion

Gold

Chong

2015

Contraception

View full text Add to dashboard Cite

“…In our study, the rate of complete abortions with methotrexate and intravaginal misoprostol for the termi nation of pregnancies < 8 weeks gestation was found to be only 71.8%, whereas Creinin [6,7], Hausknecht [9] and Schaff [10] reported 90, 96 and 97% success rates, respec tively. Several reasons may account for this significant difference.…”

Section: Discussionmentioning

confidence: 55%

Efficacy of Methotrexate and Misoprostol for Early Abortion

Özeren¹,

Çorakçi²,

Yücesoy³

et al. 1997

Gynecol Obstet Invest

View full text Add to dashboard Cite

Background: Medical termination of pregnancy (medical abortion) as an alternative to surgical abortion has many advantages since it does not require anesthetics and there is no risk of cervical laceration or uterine perforation. In the present study, we evaluated the efficacy of methotrexate and intravaginally administered misoprostol for early abortion. Methods: The study population consisted of 32 women seeking abortion of a normal intrauterine pregnancy of 8 weeks or less documented by ultrasound. The dose of methotrexate was 50 mg/m² intramuscularly and the dose of misoprostol was 800 µg intravaginally. The final outcome of treatment was evaluated on day 14 or 16, and an abortion was considered successful if pregnancy was terminated without a surgical procedure. Results: Abortion occurred in only 23 (71.8%) of 32 women. There were 9 failures (28.1%); 3 were ongoing pregnancies (9.3%) and 6 were incomplete abortions (18.7%) requiring suction curettage. After the exclusion of treatment failures, the mean duration of vaginal bleeding was 16.3 ± 2 days. No serious side effects occurred as a result of methotrexate and misoprostol treatment. Conclusion: The use of methotrexate and intravaginal misoprostol for the termination of pregnancy requires larger studies to determine the safety and efficacy of this medical abortion, a comparison with RU 486 in prospective controlled randomized trials is necessary.

show abstract

“…Methotrexate is teratogenic and may induce abortion (275,296,312,329). Methotrexate is toxic to embryonic or trophoblastic tissues and has been used to terminate ectopic pregnancies (330).…”

Section: Adverse Effects Of Methotrexatementioning

confidence: 99%